

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018454 A1

(51) International Patent Classification⁷: **C07D 401/12**

[IL/IL]; Katzenelson St. 23B/17, Herzliya 46290 (IL).
NIDAM, Tamar [IL/IL]; Rechov Weizman 53/40, Yehud
56238 (IL).

(21) International Application Number:
PCT/US2003/026544

(22) International Filing Date: 21 August 2003 (21.08.2003)

(74) Agents: **BRAINARD, Charles R.** et al.; Kenyon &
Kenyon, One Broadway, New York, N Y 10004-1050 (US).

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
60/404,845 21 August 2002 (21.08.2002) US
60/418,056 11 October 2002 (11.10.2002) US

(71) Applicant (*for all designated States except BB, US*): **TEVA
PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5
Basel Street, P.O. Box 1390, 49131 Petah Tiqva (IL).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for BB only*): **TEVA PHARMACEUTICALS
USA, INC.** [US/US]; 1090 Horsham Road, P.O. Box 1090,
Nowrth Wales, PA 19454-1090 (US).

(72) Inventors; and

Published:

(75) Inventors/Applicants (*for US only*): **SINGER, Claude**
[IL/IL]; 8/8 David Elazar, Kfar Saba 44358 (IL). **LIBER-
MAN, Anita** [IL/IL]; Rechov Ben-Joseph 28, Tel-Aviv
(IL). **VEINBERG, Irena** [IL/IL]; 42 Hanassi HArishon
Str., Apt. 28, Rehovot 76302 (IL). **FINKLESTEIN, Nina**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 2004/018454 A1

(54) Title: A METHOD FOR THE PURIFICATION OF LANSOPRAZOLE

(57) Abstract: The present invention provides a method for preparing a substantially pure lansoprazole containing less than about 0.2% (w/wt) impurities including sulfone/sulfide derivatives. The present invention also provides a process for recrystallizing lansoprazole to obtain a lansoprazole containing less than about 0.1 % (w/wt) water.

A METHOD FOR THE PURIFICATION OF LANSOPRAZOLE

CROSS-REFERENCE TO RELATED APPLICATIONS


This application claims the benefit of the U.S. Provisional Application Serial
5 Nos. 60/404,845 filed August 21, 2002 and 60/418,056 filed October 11, 2002, the
disclosures of which are incorporated by reference in their entirety herein.

FIELD OF THE INVENTION

The present invention relates to a method for preparing a substantially pure 2-(2-
10 pyridylmethyl) sulfinyl-1*H*-benzimidazole (lansoprazole) that is free of sulfone and
sulfide derivatives. The present invention also relates to a method of preparing a
lansoprazole containing <0.1% (wt/wt) water.

BACKGROUND OF THE INVENTION

Several substituted 2-(2-pyridylmethyl) sulfinyl-1*H*-benzimidazole derivatives
are well-known gastric proton pump inhibitors. These benzimidazole derivatives include
lansoprazole, omeprazole, pantoprazole, and rabeprazole. This class of benzimidazole
derivatives is generally represented by the following chemical formula A:



A

U.S. Pat. No. 4,628,098 describes the generic lansoprazole compound.
Lansoprazole has as its chemical name (2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-
pyridinyl]methyl] sulfinyl]-1*H*-benzimidazole), i.e., when R₁ is methyl, R₂ is trifluoro-
30 ethoxy, R₃ is hydrogen and R₄ is hydrogen.

As a characteristic shared with other benzimidazole derivatives (e.g., omeprazole and pantoprazole), lansoprazole can inhibit gastric acid secretion, and thus commonly used as an antiulcer agent.

5 Several methods for preparing lansoprazole are known. The majority of these methods involve the use of a lansoprazole precursor that contains a thioether group. The thioether group is oxidized in the last step of preparation to form the lansoprazole.

10 U.S. Pat. Nos. 4,628,098 and 5,578,732 (the '732 patent) describe the oxidation of the thioether group using m-chloro-perbenzoic acid as the oxidizing agent. However, the use of m-chloro-perbenzoic acid often results in a non-selective oxidation of the thioether group. The '732 patent further describes an oxidation method with hydrogen peroxide (H_2O_2) in the presence of a specific vanadium catalyst. Other patents such as ES 2105953, WO 0121617, ES 2063705, U.S. Pat. No. 6,313,303, WO9947514,
15 WO0168594 describe the use of other oxidation reagents and/or other catalysts. None of these oxidation methods result in selective oxidation of the thioether group.

20 In addition, the preparation of lansoprazole by conventional methods is always accompanied by the formation of small quantities of the corresponding sulfone derivative as an impurity. For example, U.S. Pat. No. 6,180,652 (the '652 patent) describes the presence of sulfone derivative. Formation of sulfone derivative brings about the drawback of low yield of the desired sulfoxide.

25 Although attempts have been made to separate the sulfone derivative from lansoprazole, it is not a simple task, given their very similar structures and physicochemical properties. For this purpose, the '652 patent describes a method which permits separation of lansoprazole from its sulfone derivative. An acetone complex of the lansoprazole salt is purified in this method.

30 Lansoprazole and other 2-(2-pyridylmethyl) sulfinyl-benzimidazole derivatives tend to lose stability and undergo decomposition when contaminated with traces of a solvent, particularly water, in their crystal structure. It is desirable that the

benzimidazole crystals be solvent free (i.e., residual solvent should be reduced to a minimum).

The '732 patent describes the crystallization of lansoprazole using a ethanol:water solvent system (vol:vol of ethanol:water is 9:1). U.S. Pat. No. 6,002,011 (the '011 patent) describes the crystallization of lansoprazole from the same ethanol:water system, containing traces of ammonia (0.03 mole NH_4OH : 1 mole lansoprazole). The '011 patent discloses a reslurry method in water, which permits to obtain more stable "solvent free" lansoprazole. The '011 patent fails to disclose the level of purity for lansoprazole. In addition, the ethanol and water are difficult to eliminate. Even after intensive drying, lansoprazole still contains solvent and is unstable under storage.

There is continuing need to obtain 2-(2-pyridylmethyl) sulfinyl-1*H*-benzimidazoles (e.g., lansoprazole) that are free of contaminants including sulfone and sulfide derivatives. There has also been a long-felt need for a method to prepare 2-(2-pyridylmethyl) sulfinyl-1*H*-benzimidazoles (e.g., lansoprazole) having reduced water content (<0.1% wt/wt water).

We discovered that "solvent free" lansoprazole can be obtained by the crystallization from different solvents. Lansoprazole obtained by this method of crystallization can be dried to <0.1% water, as is required by the USP forum.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a method of purifying lansoprazole, especially to 0.20% impurities or less, which method includes the steps of: providing a solution of lansoprazole in a solvent selected from an organic solvent, especially an alcohol (especially ethanol), acetone, 2-butanone, dimethyl-formamide and tetrahydrofuran, or a mixture of organic solvent and water in the presence of an amine compound, especially ammonia, ammonium hydroxide, diethyl amine, triethyl amine, or methyl amine, especially in equimolar ratio (or higher) to the lansoprazole; combining the provided solution with an acid, especially acetic acid, formic acid, or hydrochloric acid; and isolating the purified lansoprazole. When the solvent is a mixture of organic solvent and water, the ratio of organic solvent to water is especially about 0.2:1 to about

3:1 and the volume-to-weight ratio of such solvent to lansoprazole is about 17:1 to about 5:1, especially about 11:1.

In another aspect, the present invention relates to a method of preparing a lansoprazole containing less than about 0.1% (wt/wt) water (i.e. for desolvation
5 lansoprazole) comprising the steps of: crystallizing, optionally in the presence of an amine compound in a mole ratio of about 0.05:1 relative to lansoprazole, especially at 50°C or less, a lansoprazole (which can be wet or dry) from solution in a solvent that is an organic solvent, especially acetone, 2-butanone, methanol, dimethyl-carbonate, and diethyl-carbonate, or a mixture of an organic solvent and water; and isolating the
10 lansoprazole containing less than about 0.1% (wt/wt) water. Crystallization can be effected by lowering the temperature of the solution, combining the solution with water (less than about 20% vol/vol), or both.

In still a further aspect, the present invention relates to a method of purifying lansoprazole to obtain lansoprazole having less than about 0.1%, wt/wt, water
15 comprising the steps of: providing a solution of lansoprazole in a solvent selected from an organic solvent, especially ethanol, or a mixture of organic solvent and water in the presence of an amine compound, wherein the amine compound is present at a ratio of about 1:1, mole:mole, relative to lansoprazole; combining the provided solution with an acid, especially acetic acid, formic acid, or hydrochloric acid; isolating the lansoprazole;
20 dissolving the isolated lansoprazole in an organic solvent selected from the group consisting of acetone, 2-butanone, methanol, dimethyl-carbonate, and diethyl-carbonate (especially acetone), optionally in the presence of an amine compound; and isolating the purified lansoprazole having less than about 0.1%, wt/wt, water.

In yet another aspect, the present invention relates to lansoprazole having less
25 than 0.20 wt-% impurities, especially when the water content is 0.1% by wt or less.

In a further aspect, the present invention relates to lansoprazole having less than 0.20 wt-% combined sulfide and sulfone derivatives, especially when the water content is 0.1 wt-% or less.

In still a further aspect, the present invention relates to lansoprazole having less
30 than 0.10% wt-% of either sulfone or sulfide derivative, especially in combination with a water content of 0.1 wt-% or less.

DETAILED DESCRIPTION OF THE INVENTION

As used herein "LNPS" refers to the sulfide-containing starting compound for lansoprazole preparation. The chemical name for LNPS is 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]thio]-1*H* benzimidazole. "LNP" refers to lansoprazole which has the chemical name of 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl-1*H* benzimidazole. The present invention provides a "substantially pure" lansoprazole. Substantially pure lansoprazole contains less than about 0.10% (wt/wt) sulfone derivative and less than about 0.10% sulfide derivative.

Water is not considered an impurity per se, but its presence in lansoprazole is undesirable. The present invention also provides lansoprazole that contains less than about 0.1% (wt/wt) water, referred to as "solvent free" (i.e. desolvated) lansoprazole.

Unless otherwise stated, % and % (wt/wt) refer to percent on a weight basis.

As used herein in connection with a numerical quantity, "<" refers to less than.

In accordance with the present invention, 2-[[3-methyl-4-(2,2,2-trifluoro ethoxy)-2-pyridinyl]thio]-1*H* benzimidazole (LNPS) is used as a starting material for preparation of 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl-1*H* benzimidazole and is dissolved in an organic solvent or a mixture of organic solvent with water. Any residue of the LNPS remaining in the final product is an impurity and difficult to remove.

Exemplary organic solvents suitable for use in the practice of the present invention include alcohols such as ethanol, methanol, n-propanol, i-propanol; ketones such as acetone and 2-butanone; dimethyl-formamide; tetrahydrofuran; and the like. Preferably, the organic solvent is ethanol.

In particular embodiments, mixtures of an organic solvent listed above with water can be used. When mixtures of organic solvent and water are used, different volume ratios (vol/vol) of organic solvent and water can be used. The organic solvent/water ratio can vary between about 0.2:1 to 3:1. Preferably, the solvent/water ratio is about 1.5:1. Use of larger solvent/water ratios may result in poor crystallization yields.

When mixtures of an organic solvent and water are used, the overall ratio, on a volume per weight basis, of solvent/water (i.e., organic solvent + water) to lansoprazole

ratio can vary between about 17:1 to about 5:1 (vol:wt). Preferably, the ratio of solvent/water to lansoprazole is about 11:1 (vol:wt).

Amine compounds are used in the practice of the present invention. The overall ratio, on a mole basis, of amine compound to lansoprazole (mol/mol) can vary between about 17:1 to about 1:1. Preferably, the amine compound:lansoprazole (mol/mol) ratio is about 7:1. Exemplary amine compounds useful in the practice of the present invention include ammonia, ammonium hydroxide, diethylamine, triethylamine, methylamine and the like. Preferably, the amine compound is ammonium hydroxide.

Preferably, ammonium hydroxide is present at a mol/mol ratio to lansoprazole of about 1:1 to about 7:1. Crystallization of lansoprazole under such conditions permits a good separation of lansoprazole from impurities, especially sulfone and/or sulfide derivatives.

In one embodiment, the present invention provides a crystallization purification method for purifying lansoprazole. Crystallization of lansoprazole from solution in an organic solvent or a mixture of organic solvent and water in the presence of an amine compound according to the crystallization purification method of the present invention results in substantially pure lansoprazole.

In the present invention, purification of lansoprazole by crystallization is achieved by acidifying (i.e. combining with acid) a solution of lansoprazole in an organic solvent or a mixture of organic solvent and water. The acid combined can neutralize the amine compound during the crystallization of lansoprazole.

Exemplary acids combined to crystallize lansoprazole include acetic acid, formic acid, hydrochloric acid (HCl) and the like. Preferably, the acid is acetic acid.

Although the purified lansoprazole obtained by the above-mentioned crystallization purification process is substantially pure and can be advantageous, it does not necessarily contain <0.1% water in accordance with the USP forum. As mentioned previously, water can have a negative impact on the long-term stability of lansoprazole (U.S. Pat. No. 6,002,011).

Thus, in another embodiment of the present invention, a method for reducing the water (i.e. desolvating) lansoprazole is provided. In this embodiment, the water content of lansoprazole, especially substantially pure lansoprazole, can be reduced to <0.1% water by crystallization from organic solvent.

Exemplary crystallizing organic solvents for obtaining lansoprazole having <1%, wt/wt, water include methanol, dimethyl-carbonate, diethyl-carbonate, acetone, 2-butanone and the like. Preferably, such crystallizing organic solvents are methanol, dimethyl-carbonate and diethyl-carbonate. Most preferably, such crystallizing organic solvent is acetone.

Crystallization of lansoprazole to obtain lansoprazole having <0.1% water can be and preferably is carried-out in the presence of an amine compound. Exemplary amine compounds include ammonia, ammonium hydroxide, diethylamine, triethylamine, methylamine and the like. Preferably, the amine compound is ammonium hydroxide.

Preferably, in this embodiment, the mole ratio of amine compound to lansoprazole (mole:mole or mole/mole) is about 0.05:1.

Preferably the lansoprazole to be desolvated is completely dissolved in the solvent before crystallization. The dissolution of lansoprazole can be promoted by the presence of small amounts of water. The presence of a small amount of water can be insured by using wet lansoprazole from the previously mentioned purification step or by adding <20% (vol/vol) water to the solvent.

The dissolution of lansoprazole to be desolvated can be performed at the crystallization solvent reflux temperature. Preferred dissolution temperatures are lower than the reflux temperature, given the reported instability of lansoprazole at higher temperatures. Preferably, the dissolution temperature does not exceed 50°C.

The crystallization yield of lansoprazole can be improved by cooling or by removing solvent or water from the crystallization system. One skilled in the art would appreciate the techniques used to remove water from a mixture of organic solvent and water include, e.g., azeotropic distillation.

The present invention can be illustrated by the following nonlimiting examples.

Example 1

Preparation of Lansoprazole Crude

Into a flask 1L ethanol was charged and cooled under stirring to 5°C. Under mixing 200 grams 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]thio]-1*H* benzimidazole (LNPS) and 3 grams vanadium acetyl acetonate were added. 110 grams *tert*-butyl-hydroperoxide solution were dropped slowly into the suspension. The suspension was maintained under mixing during 4 hours. 40 grams of Na₂SO₃ dissolved

in 400 mL water were added. Separate solid phase by vacuum filtration and dry. 165 grams of LNP crude were obtained (yield 79 %).

Sulfone 0.3%

LNPS 0.3%

5 Chromatographic purity method of lansoprazole monograph in USP Forum Vol. 26(5) [Sept.-Oct. 2000].

HPLC Condition:

Column:	C18
Mobile phase:	Gradient of triethylamine in water with acetonitrile
10 Flow:	0.8 mL/min
Detection:	285 nm

This chromatographic assay has the detection sensitivity of less than 0.1% impurities in LNP.

15

Example 1A

Preparation of Lansoprazole crude

Into a flask 1L ethanol (95%) was charged and cooled under stirring to 5°C. Under mixing 200 grams 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl] thio]-1H benzimidazole (LNPS) and 3 grams vanadium acetyl acetate were added. 110 grams *tert*-butyl-hydroperoxide solution were dropped slowly into the suspension. The suspension was maintained under mixing during 6 hours. 40 grams of Na₂SO₃ dissolved in 400 ml water were added.

25 1L of water (pH was about 8-8.5; the pH was adjusted by the addition of NH₄OH) was added to the suspension and the suspension was further mixed for 17 hours at 25°C. The suspension was cooled to 5°C and the solid phase separated by vacuum filtration then dried. 178 grams of LNP crude were obtained (yield 85 %). Sulfone 0.15%.

30 Example 2

Purification of Lansoprazole

In a 0.25 L flask 67.5 mL ethanol 95%, 15 mL of ammonium hydroxide (NH₄OH) 24% and 45 mL water were charged and cooled under stirring to 5°C. Under mixing 10 grams lansoprazole crude were added and heated to 52°C to dissolution. 1

gram of active carbon was added to the slightly turbid solution and maintained a short time at 49°C. The carbon was separated on a filter and the cake washed with a mixture of 14 mL ethanol and 12 mL water. The solution was cooled and lansoprazole was precipitated by the addition of 3.75 mL acetic acid. The suspension was cooled to 10°C and filtered. The product was washed with water and ethanol and dried. 8.7 grams of lansoprazole pure were obtained (yield: 89%). Sulfone 0.05%, LNPS under the detection limit.

The above-described procedure was applied in other examples where the solvent and/or the amine was different. The following table is illustrative for these examples:

Example	Solvent	water	Amine	Yield	Sulfone	LNPS
		yes/no		%	%	%
3	i-propanol	no	NH ₄ OH	52.7	0.03	0.02
4	Ethanol	no	NH ₄ OH	46.5	0.07	<DL ¹
5	n-propanol	yes	NH ₄ OH	91.5	0.08	0.04
6	i-propanol	yes	NH ₄ OH	90.8	0.07	<DL
7	Ethanol	yes	Triethylamine	87.6	0.05	<DL
8	i-buthanol	yes	Triethylamine	80.7	0.06	<DL

¹ less than detection limit

Example 9

Preparation of Lansoprazole Containing <0.1% (wt/wt) Water

In a 0.25L flask 29.8 grams wet LNP crystal and 30 mL acetone were charged. The suspension was heated to 52°C and 150 mL acetone was dropped until a clear solution was obtained. The solution was cooled to 10°C and concentrated until the weight of the reaction mass was 48.5 grams. The solid was separated by filtration and washed with 20 mL cold acetone. After drying 18.58 grams product were obtained (yield: 91%). Content of water according to Karl Fischer test 0.05%.

Similar to example 3, the following other examples were performed:

Examples	Solvent	Yield	Water
		%	%(KF ¹)
10	Dimethylcarbonate	87.5	0.04

11	2-butanone	88.5	0.03
12	Methanol	72%	0.06

¹Karl Fisher method for Water determination is the USP method as written in USP Forum Vol. 26(5) [Sept.- Oct. 2000].

5 **Example 13**

Preparation of Lansoprazole Containing <0.1% (wt/wt) Water

In a 0.1 L flask 4 grams dry LNP crystals and 60 mL acetone containing 15% water were charged. The solution was maintained under mixing at 25°C for 17 hours. The solution was concentrated to 15 grams and filtered. After drying 3.4 grams
10 product were obtained (yield: 84.7%). Content of water according to Karl Fischer test: 0.06%.

Example 14

Preparation of Lansoprazole Containing <0.1% (wt/wt) Water

15 In a 50 mL flask 11.6 mL acetone, 3.1 mL water and 0.05 mL NH₄OH were charged. The solution was heated to 45°C and under mixing 5.8 grams of LNP crystal were charged. The solution was heated to 61°C and immediately cooled to 5-10°C. After filtration and drying 5.0 grams product was obtained (yield: 87%). Content of water according to Karl Fischer test: 0.03%.

20

Example 15

Lansoprazole (5.0 grams) was dissolved in 30 ml of acetone, containing 15 volume % of water, at heating at reflux. Water (30 ml) was added dropwise for 5 min to the clear solution. After cooling to room temperature the slurry was filtered, giving after
25 drying 4.5 grams of the product (yield: 90%). Content of the water according to Karl Fischer test was 0.08%.

Example 16

Lansoprazole (5.0 grams) was dissolved in 30 ml of acetone, containing 15
30 volume % of water, at heating at reflux. Water (60 ml) was added dropwise for 5 min to the clear solution. After cooling to room temperature the slurry was filtered, giving after

drying 4.6 grams of the product (yield: 92%). Content of the water according to Karl Fischer test was 0.08%.

5 A number of embodiments of the present invention have been described. The present invention is not to be limited in scope by the specific embodiments described herein. It will be understood that various modifications may be made without departing from the spirit and scope of the invention. Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

What is claimed is:

1. A method of purifying lansoprazole, comprising the steps of:
 - a) providing a solution of lansoprazole in a solvent selected from an organic solvent or a mixture of organic solvent and water in the presence of an amine compound;
 - 5 b) combining the provided solution with an acid, and
 - c) isolating the purified lansoprazole.
2. The method of claim 1 wherein the amine compound is present in 1:1, mole:mole, ratio relative to the lansoprazole.
3. The method of claim 1, wherein solution is in an organic solvent selected from
10 the group consisting of an alcohol, acetone, 2-butanone, dimethyl-formamide and tetrahydrofuran.
4. The method of claim 4, wherein the organic solvent is the alcohol ethanol.
5. The method of claim 1, wherein the amine compound is selected from the group consisting of ammonia, ammonium hydroxide, diethylamine, triethylamine and
15 methylamine.
6. The method of claim 5 wherein the amine compound is ammonium hydroxide.
7. The method of claim 6 wherein the ammonium hydroxide is present at a mol/mol ratio to lansoprazole of greater than 1.
8. The method of claim 1 wherein the acid combined is selected from the group
20 consisting of acetic acid, formic acid, and hydrochloric acid.
9. The method of claim 8 wherein the acid is acetic acid.
10. A method of preparing a lansoprazole containing less than about 0.1% (wt/wt) water, comprising the steps of:
 - a) crystallizing a lansoprazole from solution in a solvent that is an organic solvent
25 or a mixture of an organic solvent and water; and
 - b) isolating the lansoprazole containing less than about 0.1% (wt/wt) water.

11. The method of claim 10 wherein the lansoprazole of step a) is crystalline.
12. The method of claim 10 wherein the lansoprazole of step a) is dry.
13. The method of claim 10 wherein the lansoprazole of claim step a) is wet.
14. The method of claim 10, wherein the organic solvent is selected from the group
5 consisting of acetone, 2-butanone, methanol, dimethyl-carbonate, and diethyl-carbonate.
15. The method of claim 14 wherein the organic solvent is acetone.
16. The method of either of claims 10 or 15 wherein the crystallization is effected by adding water to the solution.
17. The method of claim 10 wherein the crystallization step is performed at a
10 temperature of about 50⁰C or less.
18. The method of claim 10 further comprising the step of cooling subsequent to the crystallization step.
19. The method of claim 10 wherein ammonium hydroxide is added before or in the course of the crystallization step.
- 15 20. A method of purifying lansoprazole to obtain lansoprazole having less than about 0.1%, wt/wt, water comprising the steps of:
 - a) providing a solution of lansoprazole in a solvent selected from an organic solvent or a mixture of organic solvent and water in the presence of an amine compound, wherein the amine compound is present at a ratio of about 1:1, mole:mole, relative to
20 lansoprazole;
 - b) combining the provided solution with an acid;
 - c) isolating the lansoprazole;
 - d) dissolving the isolated lansoprazole in an organic solvent selected from the group consisting of acetone, 2-butanone, methanol, dimethyl-carbonate, and diethyl-
25 carbonate; and
 - e) isolating the purified lansoprazole having less than about 0.1%, wt/wt, water.
21. The lansoprazole made by the method of any of claims 1, 10, and 20.

22. Lansoprazole containing less than 0.20% (wt/wt) impurities.
23. The lansoprazole of claim 22 containing less than 0.1%, wt/wt, water.
24. Lansoprazole containing less than 0.20%, wt/wt, combined sulfide and sulfone derivatives.
- 5 25. The lansoprazole of claim 24 containing less than 0.1%, wt/wt, water.
26. Lansoprazole containing less than 0.10%, wt/wt, sulfide derivative.
27. The lansoprazole of claim 26 containing less than 0.1%, wt/wt, water.
28. Lansoprazole containing less than 0.10%, wt/wt, sulfone derivative.
29. The lansoprazole of claim 28 containing less than 0.1%, wt/wt, water.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/26544

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 002 011 A (ISHIDA TORU ET AL) 14 December 1999 (1999-12-14) cited in the application	10-19, 21-29
Y	claims example 1	1-9,20
Y	US 6 268 502 B1 (JEREB DARJA ET AL) 31 July 2001 (2001-07-31) claim 1; example 1	1-9,20
Y	US 6 166 213 A (BANKS BENJAMIN NEWTON ET AL) 26 December 2000 (2000-12-26) claim 5; example 2	1-9,20
X	US 5 578 732 A (KATO MASAYASU ET AL) 26 November 1996 (1996-11-26) cited in the application example 4	10-19, 21-29

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

14 November 2003

Date of mailing of the international search report

26/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stroeter, T

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US 03/26544

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6002011	A	14-12-1999	AT 240314 T	15-05-2003
			AU 731776 B2	05-04-2001
			AU 4965297 A	03-06-1998
			CN 1237167 A	01-12-1999
			DE 69722027 D1	18-06-2003
			DK 944617 T3	01-09-2003
			EP 0944617 A1	29-09-1999
			WO 9821201 A1	22-05-1998
			JP 10195068 A	28-07-1998
			KR 2000053158 A	25-08-2000
			NZ 335145 A	22-12-2000
			TR 9901055 T2	21-07-1999
			TW 385306 B	21-03-2000
			ZA 9710255 A	13-05-1999
US 6268502	B1	31-07-2001	SI 20019 A	29-02-2000
			AT 216382 T	15-05-2002
			AU 4671499 A	01-02-2000
			DE 69901307 D1	23-05-2002
			EP 1095037 A1	02-05-2001
			HU 0102523 A2	28-11-2001
			NZ 509000 A	21-12-2001
			PL 345543 A1	17-12-2001
			RU 2197486 C2	27-01-2003
			WO 0002876 A1	20-01-2000
			SI 1095037 T1	31-08-2002
			SK 252001 A3	10-07-2001
US 6166213	A	26-12-2000	US 2002007069 A1	17-01-2002
			US 6147103 A	14-11-2000
			US 6191148 B1	20-02-2001
			AU 764642 B2	28-08-2003
			AU 5470999 A	06-03-2000
			BR 9912883 A	25-09-2001
			CA 2338967 A1	24-02-2000
			CN 1322201 T	14-11-2001
			EP 1104417 A1	06-06-2001
			JP 2002522537 T	23-07-2002
			NO 20010677 A	09-04-2001
			NZ 509798 A	30-06-2003
US 5578732	A	26-11-1996	WO 0009497 A1	24-02-2000
			ZA 200101140 A	09-04-2002
			AT 82283 T	15-11-1992
			CA 1263119 A1	21-11-1989
			DE 3875848 D1	17-12-1992
			DE 3875848 T2	25-03-1993
			DK 171989 B1	08-09-1997
			EP 0302720 A1	08-02-1989
			ES 2052728 T3	16-07-1994
			GR 3006974 T3	30-06-1993
			HU 49346 A2	28-09-1989
			IE 61717 B1	30-11-1994
			JP 1131176 A	24-05-1989
			JP 1959606 C	10-08-1995
			JP 6086444 B	02-11-1994
			KR 9600047 B1	03-01-1996

Form PCT/ISA/210 (patent family annex) (July 1992)

THIS PAGE BLANK (USPTO)